HIV vaccine breakthrough in discovery of ‘on-off switch’
- Researchers have discovered how to generate an ‘on-off’ switch in a form of HIV
- HIV needs a specific amino acid to replicate so researchers replaced the code that does this with a ‘nonsense’ version that halts amino acid production
- When the supply of amino acids stopped, so did the replication
- This technique gave the team control over the virus’s replication
Mary Kekatos For Dailymail.com
46
View
comments
A breakthrough has occurred in the fight against HIV, new research reveals.
Scientists say they’ve engineered an ‘on-off switch’ into a weakened form of HIV, enhancing the safety and effectiveness of a potential vaccine for the virus.
They say this could be the final necessary step to eradicate the disease that’s killed 35 million people since the beginning of the epidemic in the 1980s.
Researchers at the University of Nebraska-Lincoln have discovered how to generate an ‘on-off switch’ into a weakened form of HIV (seen here in the bloodstream)
Vaccinologists often prefer exposing the body to weakened viruses, rather than deactivated ones, because they grant stronger and longer-lasting immunity.
But weakened viruses retain the ability to replicate, meaning that they still pose a risk of becoming full-blown pathogens.
Researchers at the University of Nebraska-Lincoln began addressing this issue in 2014, when they genetically engineered a version of HIV that needs a synthetic amino acid – one not found in the body – to replicate.
-
Hepatitis B and C virus may be linked to increased risk of…
Association with HIV/AIDS charity omitted from China’s (RED)…
Doing so required the team to replace a codon that codes for the amino acid in the HIV’s genetic code.
NEW COMBINATION OF DRUGS COULD ELIMINATE HIV
HIV could be eliminated using a novel combination of drugs, claims a research team on the brink of an unprecedented experiment.
Scientists at Case Western Reserve University’s medical school have been granted $2.5 million to try pairing two never-before-combined AIDS treatments in a human clinical trial.
The properties – a natural protein that kills disease and a lab-made antibody – have been separately used in HIV-suppressing drugs for years.
Our current line-up of medication is highly effective: roughly 30 percent of America’s 1.2 million people with HIV have reached an undetectable viral load – meaning treatment has suppressed the virus to the point it is untransmittable.
But lead researcher Dr Michael M Lederman believes a combination of these two properties could ‘produce more of a wallop in tandem than when administered individually’.
Each codon instructs an amino acid to connect to a chain that becomes a protein and ultimately allows viral replication.
The team swapped out one of these codons for a ‘nonsense’ version that instead signals a stop in the amino-acid assembly line, halting production of the proteins essential for replication.
When the team supplied the synthetic amino acid, the assembly line began churning out proteins, and the virus began replicating. When the supply of amino acids stopped, so did the replication.
This technique gave the team control over the HIV’s replication. And by delivering a consistent supply of amino acids, the team showed that it can kick-start the multiple cycles of replication necessary for an effective vaccine.
‘Safety is always our biggest concern,’ said Dr Wei Niu, an associate professor of chemical and biomolecular engineering.
‘In this case, [it means] we’re one step closer to generating a vaccine.’
Other research teams have managed to generate HIV immunity in organisms, with one vaccine protecting 95 percent of rhesus monkeys against the virus.
Many of these vaccines have relied on deleting HIV genes to limit replication, but the virus’ penchant for mutating can help it overcome this defense and replicate unchecked.
Dr Qingsheng Li, a professor of biological sciences, said the team’s combination of a nonsense codon, genetic switch and synthetic amino acid represents an especially rigid set of safeguards against unchecked replication.
‘That’s the big milestone,’ said Dr Li.
‘If that works well, we need to go to the pre-clinical animal model before going to a clinical trial. That’s our goal and road map.’
Share or comment on this article
- ‘It attacked from behind’: Farmer swallowed whole by…
- ‘Sharnie was the most natural mother in the world’: NRL…
- Mother and her son, 13, die and his company director…
- Snake gets its comeuppance after attacking a porcupine…
- ‘You owe me’: Top Harefield heart surgeon ‘raped mother…
- FBI pictures reveal fiery aftermath and appalling…
- Man, 20, ‘raped and killed his girlfriend’s four-year-old…
- Road to Damascus moment: Syrian millionaire, 38, GIVES…
- ‘The EU has ruined this country’: Furious pensioner, 70,…
- Out on the town AGAIN! Malia Obama dines out with a…
- Man tries to abduct three-year-old British girl at Costa…
- EXCLUSIVE – Bird of paradise: Bikini-clad Megyn Kelly…
- Woman who tried to lure a toddler from her mother by…
- Romanian 18-year-old girl claims she has sold her…
- PICTURED: Dog owner mauled to death by his own Staffie in…
- Pay up first – THEN we’ll talk! EU leaders threaten…
- ‘My rule is that if my Grandad would be disgusted, I’d…
- Devastated mother, 47, discovered via FACEBOOK her…
Comments 46
Share what you think
-
Newest -
Oldest -
Best rated -
Worst rated
The comments below have not been moderated.
The views expressed in the contents above are those of our users and do not necessarily reflect the views of MailOnline.
Close
Your comment will be posted to MailOnline as usual.
Your comment will be credited to your MailOnline persona.
Close
Your comment will be posted to MailOnline as usual
We will automatically post your comment and a link to the news story to your Facebook timeline at the same time it is posted on MailOnline. To do this we will link your MailOnline account with your Facebook account. We’ll ask you to confirm this for your first post to Facebook.
The post will be credited to your MailOnline username. You can choose on each post whether you would like it to be posted to Facebook. Your details from Facebook will be used to provide you with tailored content, marketing and ads in line with our Privacy Policy.